MedCity News
Melinta antibiotic for MRSA & other serious skin infections wins FDA approval
Melinta Therapeutics already sells an antibiotic for serious skin infections. But FDA approval of Kimyrsa gives clinicians another option to offer patients, one with more convenient dosing.
Shares0
Melinta Therapeutics can now add another antibiotic to its portfolio after the FDA on Monday approved the company’s infused treatment for serious skin infections such as MRSA.
Approval of oritavancin, which will be marketed under the name Kimyrsa, covers the treatment of acute bacterial skin and skin structure infections (ABSSSI). The New Haven, Connecticut-based company already sells another oritavancin-based product, Orbactiv. But Kimyrsa will offer the prospect of a single, one-hour infusion compared to Orbactiv, which is infused over the course of three hours. Approved in 2014, Orbactiv was developed as an alternative to vancomycin, an antibiotic that is infused twice daily for sev
CMS has increased the Medicare payment rate by $12 for administering single-dose Covid-19 vaccines and by $35 for two-dose vaccines. The payment increase aims to support providers as they ramp up vaccine administration.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Hanna Helms
Hanna Helms is a manager with AVIA’s Center for Care Transformation which focuses on population health, specialty care, and health equity. Recently, she led the behavioral health and substance use disorder initiatives of the Medicaid Transformation Project. In her role, she conducts extensive research and due diligence on digital health solutions, interfaces with health system leadership to develop strategy and business plans for implementing digital solutions, and leads project management efforts across multiple engagements. Prior to AVIA, she worked at the Advisory Board on their health IT research team.